Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.
It has been previously shown that acute myeloid leukemia (AML) patients with higher levels of GATA1 expression have poorer outcomes. Furthermore, pediatric Down syndrome (DS) patients with acute megakaryocytic leukemia (AMKL), whose blast cells almost universally harbor somatic mutations in exon 2 o...
Main Authors: | John Timothy Caldwell, Holly Edwards, Alan A Dombkowski, Steven A Buck, Larry H Matherly, Yubin Ge, Jeffrey W Taub |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3707876?pdf=render |
Similar Items
-
Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation.
by: Hamlett, I, et al.
Published: (2008) -
GATA2 mutations and overexpression in pediatric acute myeloid leukemia
by: Zhenzhen Yang, et al.
Published: (2019-08-01) -
Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model
by: Brahim Arkoun, et al.
Published: (2023-04-01) -
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay
by: Juban, G, et al.
Published: (2020) -
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay
by: Gaëtan Juban, et al.
Published: (2020-06-01)